Shares of Astellas Pharma Inc. (OTCMKTS:ALPMY - Get Free Report) crossed above its 50-day moving average during trading on Wednesday . The stock has a 50-day moving average of $9.62 and traded as high as $9.99. Astellas Pharma shares last traded at $9.91, with a volume of 67,192 shares trading hands.
Astellas Pharma Stock Down 1.7 %
The company has a quick ratio of 0.80, a current ratio of 1.04 and a debt-to-equity ratio of 0.39. The company has a market cap of $17.93 billion, a P/E ratio of -45.04 and a beta of 0.31. The business's 50 day moving average is $9.63 and its 200 day moving average is $10.01.
Astellas Pharma (OTCMKTS:ALPMY - Get Free Report) last released its quarterly earnings results on Friday, April 25th. The company reported $0.27 earnings per share for the quarter, beating analysts' consensus estimates of $0.15 by $0.12. Astellas Pharma had a negative net margin of 3.10% and a positive return on equity of 13.69%. The business had revenue of $3.22 billion for the quarter, compared to analysts' expectations of $3.02 billion. As a group, equities analysts anticipate that Astellas Pharma Inc. will post 0.42 earnings per share for the current fiscal year.
Astellas Pharma Company Profile
(
Get Free Report)
Astellas Pharma Inc manufactures, markets, and imports and exports pharmaceuticals in Japan and internationally. The company provides XTANDI, a treatment for prostate cancer; XOSPATA, a treatment for patients who have relapsed or refractory acute myeloid leukemia with a FLT3 mutation; and PADCEV, a treatment for patients with metastatic urothelial cancer.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Astellas Pharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Astellas Pharma wasn't on the list.
While Astellas Pharma currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
